Mirum Pharmaceuticals, Inc. (MIRM) FY2026 Q2 P&L / Income Statement

Mirum Pharmaceuticals, Inc. (MIRM) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Product sales, net

176,243,000 US dollars

Total operating expenses

218,780,000 US dollars

Loss from operations

negative 42,537,000 US dollars

Other income (expense), net (calculated)

negative 23,001,000 US dollars

Net loss before provision for income taxes

negative 65,538,000 US dollars

Provision for income taxes

1,689,000 US dollars

Net loss

negative 67,227,000 US dollars

Livmarli

128,721,000 US dollars

Bile Acid Medicines

47,522,000 US dollars

Total operating expenses

218,780,000 US dollars

Chart connections

• Revenue minus operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.